{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:16:22Z","timestamp":1787991382506,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.obpill.2026.100288","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:04:46Z","timestamp":1781712286000},"page":"100288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-9175","authenticated-orcid":false,"given":"Theresa Hunter","family":"Gibble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-2205","authenticated-orcid":false,"given":"Harriet","family":"Makin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2707-4646","authenticated-orcid":false,"given":"Elizabeth","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7539-1777","authenticated-orcid":false,"given":"Angela","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-1408","authenticated-orcid":false,"given":"Harold","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2026.100288_bib1","author":"Organization"},{"key":"10.1016\/j.obpill.2026.100288_bib2","author":"Federation"},{"key":"10.1016\/j.obpill.2026.100288_bib3","author":"Federation"},{"issue":"4","key":"10.1016\/j.obpill.2026.100288_bib4","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/15598276241309248","article-title":"Breaking the silence on obesity","volume":"19","author":"Cepni","year":"2025","journal-title":"Am J Lifestyle Med"},{"issue":"3","key":"10.1016\/j.obpill.2026.100288_bib5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41366-024-01599-z","article-title":"Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy","volume":"49","author":"Anazco","year":"2025","journal-title":"Int J Obes"},{"issue":"8","key":"10.1016\/j.obpill.2026.100288_bib6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer \u2014 viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.obpill.2026.100288_bib7","first-page":"S145","article-title":"Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in Diabetes\u20132024","volume":"47","year":"2023","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.obpill.2026.100288_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2025.07.017","article-title":"American association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with Obesity\/adiposity-based chronic disease \u2013 2025 update","volume":"31","author":"Nadolsky","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.obpill.2026.100288_bib9","author":"Uspi"},{"issue":"3","key":"10.1016\/j.obpill.2026.100288_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10402","key":"10.1016\/j.obpill.2026.100288_bib11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.obpill.2026.100288_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.obpill.2026.100288_bib13","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.obpill.2026.100288_bib14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s13300-025-01723-w","article-title":"Tirzepatide was associated with improved health-related quality of life in adults with obesity or overweight and type 2 diabetes: results from the phase 3 SURMOUNT-2 trial","volume":"16","author":"Hunter","year":"2025","journal-title":"Diabetes Therapy"},{"issue":"8","key":"10.1016\/j.obpill.2026.100288_bib15","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1111\/dom.16463","article-title":"Tirzepatide and health-related quality of life in adults with obesity or overweight: results from the SURMOUNT-3 phase 3 randomized trial","volume":"27","author":"Gibble","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.obpill.2026.100288_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/dom.16046","article-title":"Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study","volume":"27","author":"Gudzune","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"11","key":"10.1016\/j.obpill.2026.100288_bib17","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/oby.70011","article-title":"Tirzepatide associated with improved health-related quality of life in adults with obesity or overweight in SURMOUNT-4","volume":"33","author":"Gibble","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"10.1016\/j.obpill.2026.100288_bib18","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s13300-023-01451-z","article-title":"Patient-reported outcomes in people with type 2 diabetes receiving tirzepatide in the SURPASS clinical trial programme","volume":"14","author":"Boye","year":"2023","journal-title":"Diabetes Ther"},{"issue":"Suppl 2","key":"10.1016\/j.obpill.2026.100288_bib19","first-page":"S80","article-title":"Understanding self-directed stigma: development of the weight bias internalization scale","volume":"16","author":"Durso","year":"2008","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.obpill.2026.100288_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bodyim.2013.09.005","article-title":"Measuring internalized weight attitudes across body weight categories: validation of the modified weight bias internalization scale","volume":"11","author":"Pearl","year":"2014","journal-title":"Body Image"},{"issue":"3","key":"10.1016\/j.obpill.2026.100288_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12310","article-title":"Validation of a new measure of quality of life in obesity trials: impact of weight on quality of life-lite clinical trials version","volume":"9","author":"Kolotkin","year":"2019","journal-title":"Clin Obes"},{"issue":"5","key":"10.1016\/j.obpill.2026.100288_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12477","article-title":"Confirmatory psychometric evaluations of the impact of weight on quality of life\u2013lite clinical trials version (IWQOL-Lite-CT)","volume":"11","author":"Kolotkin","year":"2021","journal-title":"Clinical Obesity"},{"issue":"8","key":"10.1016\/j.obpill.2026.100288_bib23","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","article-title":"International physical activity questionnaire: 12-Country reliability and validity","volume":"35","author":"Craig","year":"2003","journal-title":"Med Sci Sports Exerc"},{"issue":"6","key":"10.1016\/j.obpill.2026.100288_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/sleep\/33.6.781","article-title":"Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments","volume":"33","author":"Buysse","year":"2010","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.obpill.2026.100288_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/15402002.2012.636266","article-title":"Development of short forms from the PROMIS\u2122 sleep disturbance and Sleep-related impairment item banks","volume":"10","author":"Yu","year":"2011","journal-title":"Behav Sleep Med"},{"key":"10.1016\/j.obpill.2026.100288_bib26","article-title":"Development and content evaluation of the eating behavior and appetite questionnaire (EBAQ) for individuals with obesity","author":"Kanu","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.obpill.2026.100288_bib27","article-title":"Psychometric validation of the eating behavior and appetite questionnaire (EBAQ) for individuals with obesity or overweight","author":"Kanu","year":"2025","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.obpill.2026.100288_bib28","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.183","article-title":"P118 content validity of the subcutaneous administration assessment questionnaire (SQAAQ) in adult and adolescent patients with moderate to severe ulcerative colitis","volume":"158","author":"Naegeli","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.obpill.2026.100288_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07853890.2022.2149849","article-title":"Country-specific reference values for PROMIS(\u00ae) pain, physical function and participation measures compared to US reference values","volume":"55","author":"Terwee","year":"2023","journal-title":"Ann Med"},{"issue":"2","key":"10.1016\/j.obpill.2026.100288_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12529-021-10008-y","article-title":"Internalized weight stigma, psychological well-being, and sleep in women","volume":"29","author":"Craven","year":"2022","journal-title":"Int J Behav Med"},{"issue":"1","key":"10.1016\/j.obpill.2026.100288_bib31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s40519-023-01582-z","article-title":"The relationship between internalized weight stigma and physical and mental health-related quality of life in a large sample of women: a structural equation modeling analysis","volume":"28","author":"Zagaria","year":"2023","journal-title":"Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity"},{"issue":"5","key":"10.1016\/j.obpill.2026.100288_bib32","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.obpill.2026.100288_bib33","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1038\/s41591-025-03774-9","article-title":"Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial","volume":"31","author":"Martin","year":"2025","journal-title":"Nat Med"},{"issue":"Supplement_1","key":"10.1016\/j.obpill.2026.100288_bib34","doi-asserted-by":"crossref","DOI":"10.2337\/db23-128-OR","article-title":"128-OR: the effect of tirzepatide during weight loss on food intake, appetite, food preference, and food craving in people with obesity","volume":"72","author":"Martin","year":"2023","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.obpill.2026.100288_bib35","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1111\/dom.70063","article-title":"Impact of tirzepatide treatment on participant-reported food craving and food preference: secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction","volume":"27","author":"Kennedy","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2026.100288_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.26817","article-title":"US state-level prevalence of adult obesity by race and ethnicity from 1990 to 2022 and forecasted to 2035","author":"DeCleene","year":"2026","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.obpill.2026.100288_bib37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.37765\/ajmc.2024.89587","article-title":"Inadequate insurance coverage for overweight\/obesity management","volume":"30","author":"Miller","year":"2024","journal-title":"Am J Manag Care"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:30:06Z","timestamp":1787988606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S2667368126000446"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100288","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eli Lilly and Company. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100288"}}